5 results
- To asses the safety and toxicity of peri-ablative sorafenib given in doses of either 200 mg or 400 mg twice daily.- To asses the effect of perioperative sorafenib on the RFA induced mobilization of endothelial progenitor cells and cytokines…
AdOpt CRT is designed to compare indices of cardiac function at device settings optimized using an investigational Adaptive CRT (aCRT)algorithm versus CRT with nominal programming. The comparison will be performed during rest and submaximal exercise…
To evaluate the efficacy and safety of BIBF 1120 in HCC patients without prior systemic treatment as compared to Sorafenib.
The revised aims of the SORCE trial are:1. Does up to three years of treatment with sorafenib increase DFS compared with placebo: a comparison of Arm C vs Arm A2. If the answer to question (i) is yes, does one year of sorafenib (Arm B) increase DFS…
1. Evaluate the relation between pretreatment muscle weaknesses, spasticity, abnormal synergies, and changes in viscoelastic joint properties on the one hand, and changes in upper extremity spasticity following treatment on the other hand in…